Affinium Pharmaceuticals announces completion of recruitment for Stage 2 clinical trial of AFN-1252 Affinium Pharmaceuticals announced that complete recruitment has been achieved in it is multi-center Phase 2 clinical trial evaluating oral AFN-1252 in acute bacterial skin & epidermis structure infections male extra . This Phase 2 trial may be the first individual efficacy study conducted with a new course of an tibiotics designed to specifically inhibit staphylococcal fatty acid biosynthesis with a new drug focus on, the fatty acid synthase II system. Outcomes expected in late 2012 will signify a substantial proof-of-concept milestone for this unique, Staphylococcus-particular antibiotic, AFN-1252. The goals of the study are to verify efficac y, basic safety and tolerability of 200 mg of oral AFN-1252 dosed daily for 5-14 times in patients with severe twice, suspected staphylococcal skin infections recruited in the emergency or outpatient room settings.
The fresh addition to the business’s patent portfolio has made the legal framework for unique use of the Alzheimer’s vaccine later on. We are pleased extremely!’ Related StoriesGHIT Fund invests $10.7 million to combat malaria, TB, leishmaniasis and dengueNew vaccine is apparently far better in reducing 'awful' LDL cholesterolBasic study for developing toxoplasma vaccine underway.. Affiris GmbH granted a Europe-wide patent for important elements of its Alzheimer’s vaccine As a result, the business has exclusive rights useful to the peptide sequences for an innovative approach to vaccine development. The tolerability of the initial Affiris vaccine, AFFITOPE Advertisement01, has been tested within a phase I clinical trial currently. The lead investor in the company, MIG-Fonds, is content with the expanding patent portfolio of Affiris GmbH extremely.